Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab in advanced CD123-positive hematological malignancies
NCT04681105Phase 1Completed
- Sponsor
- City of Hope
- Start
- Nov 2020
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of flotetuzumab in acute lymphoblastic leukemia (ALL), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CML) and 5 more, sponsored by City of Hope. Started Nov 2020; status: completed.
02
Drugs
flotetuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)chronic myelogenous leukemia (CML)hairy cell leukemia (HCL)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT04681105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681105.